English

NattoPharma releases Q1 2021 Trading Update

Report this content

Oslo, Norway (12 May 2021)

NattoPharma reports revenues of NOK 49.9 million for the quarter, a decrease of 11% compared to the same quarter last year. Underlying volumes decreased by 7%.
 

YTD Adjusted EBITDA came in at NOK 11.0 million, equal to a margin of 21.9%.

Performance highlights for Q1 2021 (Q1 2020 in brackets)

  • Operating revenue of NOK 49.9m (NOK 56.3m)
  • Adjusted EBITDA of NOK 11.0m (NOK 10.5m)
  • Adjusted EBITDA margin of 21.9% (18.7%)
  • Our supply situation, including Natural supply from India, is flowing as normal, with no current delays despite COVID-19

CEO, Kjetil Ramsøy:

“The first quarter topline performance is in line with our expectations albeit lower than Q1 2020 which was heavily impacted by both the start of the pandemic last year and a very strong USD. It is gratifying to see that our profitability is at an Adj. EBITDA of nearly 22% in the quarter, creating a solid basis for achieving our full-year guiding. During Q1 we continued to build our inventory position and maintained a strong focus on our working capital to ensure we can meet the growth expectations in 2021.”

Acquisition by Lesaffre

On 20 April 2021 Lesaffre announced the launch of their mandatory offer on NattoPharma ASA and the offer is expected to conclude on May 18, 2021. More information will be available when the mandatory offer has been completed.

For more information, please contact:

Robert Schrama, CFO, NattoPharma, robert.schrama@nattopharma.com

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Documents & Links